Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vaccine Candidate #1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | mRNA influenza vaccine candidate #1 as a single intramuscular (IM) injection on Day 1. |
| B | EXPERIMENTAL | mRNA influenza vaccine candidate #2 as a single IM injection on Day 1. |
| C | EXPERIMENTAL | mRNA influenza vaccine candidate #3 as a single IM injection on Day 1. |
| D | EXPERIMENTAL | mRNA influenza vaccine candidate #4 as a single IM injection on Day 1. |
| E | EXPERIMENTAL | mRNA influenza vaccine candidate #5 as a single IM injection on Day 1. |
| F | EXPERIMENTAL | mRNA influenza vaccine candidate #6 as a single IM injection on Day 1. |
| G | ACTIVE_COMPARATOR | Licensed influenza vaccine (TIV1 or TIV2) as a single IM injection. |
| Name | Type | Description |
|---|---|---|
| Vaccine Candidate #1 | BIOLOGICAL | Investigational influenza Vaccine |
| Vaccine Candidate #2 | BIOLOGICAL | Investigational influenza Vaccine |
| Vaccine Candidate #3 | BIOLOGICAL | Investigational Influenza Vaccine |
| Vaccine Candidate #4 | BIOLOGICAL | Investigational Influenza Vaccine |
| Vaccine Candidate #5 | BIOLOGICAL | Investigational Influenza Vaccine |
| Vaccine Candidate #6 | BIOLOGICAL | Investigational Influenza Vaccine |
| TIV1 or TIV2 | BIOLOGICAL | Licensed influenza vaccine |
Inclusion Criteria • Healthy and medically stable participants who are determined by medical history, physical examination (if clinically required), and clinical judgment of the investigator to be eligible for inclusion in the study. Exclusion Criteria * Tested positive for influenza ≤5 months (1...
Vaccine Candidate #1 is an investigational mRNA vaccine developed by Pfizer, Inc. (NYSE: PFE). It is being studied in healthy adults as a potential vaccine against influenza. The candidate is currently in Phase 2 clinical development and has not been approved for any use.
Vaccine Candidate #1 is being developed for immunization against influenza in healthy adults. It is an investigational mRNA vaccine and is not yet approved or available for use outside of clinical trials. Its only registered study enrolls healthy adult volunteers aged 18 years and older.
Vaccine Candidate #1 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor of the clinical program evaluating this mRNA influenza vaccine candidate in healthy adult volunteers.
Vaccine Candidate #1 is in Phase 2 clinical development. It is an investigational product and has not been approved by the FDA or any other regulatory agency. The program has one registered trial, which is currently recruiting participants.
Vaccine Candidate #1 is being evaluated in one registered clinical trial, NCT07431853, titled A Study to Learn About mRNA Vaccines Against Influenza in Adults. The Phase 2 trial is recruiting and plans to enroll 770 healthy adults aged 18 and older in the United States. It is randomized, double blind, and active controlled.